胶原酶治疗掌腱膜挛缩症的临床结果：一项为期2年随访的病例系列研究
CLINICAL RESULTS OF COLLAGENASE TREATMENT FOR DUPUYTREN'S DISEASE: A CASE SERIES STUDY WITH 2-YEARS FOLLOW-UP.
作者信息
Basso Morena Anna, Bernasconi Alessio, Balato Giovanni, Cozzolino Andrea, Famiglietti Giulia, Smeraglia Francesco
机构信息
"Federico II" University, Department of Public Health, Division of Orthopaedic Surgery, Naples, Italy.
出版信息
Acta Ortop Bras. 2023 Apr 17;31(spe1):e259218. doi: 10.1590/1413-785220233101e259218. eCollection 2023.
OBJECTIVES
This study aims to report our experience with Clostridium Histolyticum collagenase (CCH) to support the importance of its clinical use and assess its clinical efficacy, complications, and recurrences.
METHODS
This prospective observational study of 66 patients with a 2-year follow-up. Patients with an extension lag major of 20° at the metacarpophalangeal joint (MPJ) and/or proximal interphalangeal joint (PIPJ) were included. We collected data on demographic and anamnestic details, MPJ and PIPJ contracture degrees, DASH score, complications, and recurrences.
RESULTS
The mean pre-injection contracture was 34° for MPJ and 31° for PIPJ. At the 2-year follow-up, the mean contracture for the MPJ and PIPJ were respectively 3° and 14.5°. The mean DASH score decreased from 21.8 before injection to 10,4 after 2 years. The disease recurrence occurred in 34.8% of the patients, all with PIPJ contracture. The main complication was skin breakage (25.7%).
CONCLUSION
The CCH injections remain a consistent option in treating DD; withdrawal from the European market deprives surgeons and patients of low invasiveness and safe tool for treating DD. .
目的
本研究旨在报告我们使用溶组织梭状芽孢杆菌胶原酶（CCH）的经验，以支持其临床应用的重要性，并评估其临床疗效、并发症和复发情况。
方法
这项前瞻性观察性研究纳入了66例患者，随访2年。纳入掌指关节（MPJ）和/或近端指间关节（PIPJ）伸展滞后大于20°的患者。我们收集了人口统计学和既往病史细节、MPJ和PIPJ挛缩程度、DASH评分、并发症和复发情况的数据。
结果
注射前MPJ平均挛缩为34°，PIPJ平均挛缩为31°。在2年随访时，MPJ和PIPJ的平均挛缩分别为3°和14.5°。DASH评分的平均值从注射前的21.8降至2年后的10.4。34.8%的患者出现疾病复发，均为PIPJ挛缩。主要并发症是皮肤破损（25.7%）。
结论
CCH注射仍然是治疗杜普伊特伦挛缩症（DD）的一个可靠选择；从欧洲市场撤出剥夺了外科医生和患者用于治疗DD的低侵入性和安全工具。
Zotero 插件